牛牛AI助理已提取核心訊息
On December 31, 2023, a filing was made with the United States Securities and Exchange Commission (SEC) by Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz, indicating that they do not hold any shares of Virpax Pharmaceuticals, Inc. The Schedule 13G/A amendment filing, which is a requirement for certain levels of ownership in a company, shows that these entities and individuals have ceased to be the beneficial owners of more than five percent of Virpax Pharmaceuticals' common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934. Sabby Management, LLC, based in Delaware, and Hal Mintz, a U.S. citizen, are associated with the Cayman Islands-based Sabby Volatility Warrant Master Fund, Ltd. The filing includes a certification that the securities were not acquired for the purpose of changing or influencing the control of Virpax Pharmaceuticals and were not held in connection with any transaction having that purpose or effect. The joint filing agreement was dated January 2, 2024.
On December 31, 2023, a filing was made with the United States Securities and Exchange Commission (SEC) by Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz, indicating that they do not hold any shares of Virpax Pharmaceuticals, Inc. The Schedule 13G/A amendment filing, which is a requirement for certain levels of ownership in a company, shows that these entities and individuals have ceased to be the beneficial owners of more than five percent of Virpax Pharmaceuticals' common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934. Sabby Management, LLC, based in Delaware, and Hal Mintz, a U.S. citizen, are associated with the Cayman Islands-based Sabby Volatility Warrant Master Fund, Ltd. The filing includes a certification that the securities were not acquired for the purpose of changing or influencing the control of Virpax Pharmaceuticals and were not held in connection with any transaction having that purpose or effect. The joint filing agreement was dated January 2, 2024.
2023年12月31日，Sabby Volatility Warrant, Master Fund, LLC、Sabby Management, LLC和Hal Mintz向美國證券交易委員會（SEC）提交了一份文件，表明這些實體和個人已不再是更多公司的受益所有人。附表13G/A修正案文件顯示，這些實體和個人已不再是更多公司的受益所有者超過Virpax Pharmaceuticals普通股的百分之五。該文件是根據1934年《證券交易法》第13d-1（c）條提交的。總部位於特拉華州的Sabby Management, LLC和美國公民哈爾·明茲與總部位於開曼群島的Sabby Volitality...展開全部
2023年12月31日，Sabby Volatility Warrant, Master Fund, LLC、Sabby Management, LLC和Hal Mintz向美國證券交易委員會（SEC）提交了一份文件，表明這些實體和個人已不再是更多公司的受益所有人。附表13G/A修正案文件顯示，這些實體和個人已不再是更多公司的受益所有者超過Virpax Pharmaceuticals普通股的百分之五。該文件是根據1934年《證券交易法》第13d-1（c）條提交的。總部位於特拉華州的Sabby Management, LLC和美國公民哈爾·明茲與總部位於開曼群島的Sabby Volitality Warrance Master Fund有限公司有關聯。該文件包括一份證明，收購這些證券不是爲了改變或影響Virpax Pharmicals的控制權，也不是爲了改變或影響Virpax Pharmicals的控制權而持有，也不是與任何具有該目的或效果的交易有關的。聯合申報協議的日期爲2024年1月2日。
有用
沒用